Hikma, Glenmark Pharmaceuticals Enter Exclusive Licensing Agreement

Generic pharmaceutical company, Hikma Pharmaceuticals, and the Swiss subsidiary of Glenmark Pharmaceuticals, Glenmark Specialty, have signed an exclusive license agreement for the commercialization of Ryaltris in the United States.

Ryaltris (olopatadine hydrochloride and mometasone furoate nasal spray) is an investigational fixed-dose combination nasal spray that has been designed for the treatment of seasonal allergic rhinitis (SAR). Under the terms of the exclusive agreement, Glenmark will take responsibility for the development and FDA regulatory approval of Ryaltris, and Hikma will be responsible for the commercialization of the nasal spray in the US post-approval.

“We are pleased to form this partnership with Glenmark, which builds on our market-leading position in nasal allergy sprays and advances our objective of growing our specialty business in the US,” said Brian Hoffmann, president of Hikma Generics, in a Feb. 27, 2020 press release. “Hikma is the largest supplier of generic nasal sprays in the US. Adding Ryaltris is a significant step forward in expanding our US nasal spray leadership into branded medicines. Importantly, it will allow us to leverage our strong, existing specialty salesforce already calling on doctors with our specialty portfolio, and to potentially leverage our nasal spray manufacturing capabilities in Columbus, Ohio. We look forward to bringing this important new treatment option to millions of US patients.” 

“We are happy to partner with Hikma in the US as Ryaltris is a perfect strategic fit in their near-term plan to build a branded nasal spray portfolio. This partnership gives us an opportunity to tap into the largest pharmaceutical market in the world. This step is aligned with our vision to make Ryaltris the first global brand of Glenmark by launching it in several markets across the globe,” added Glenn Saldanha, chairman and managing director of Glenmark Pharmaceuticals, in the press release.

Source: Hikma